News

Visus Therapeutics announced today that FDA has approved its Investigational New Drug Application (IND) to move forward with the clinical development program for BRIMOCHOL

Graybug Vision, Inc. has reported preliminary topline data from a 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

A Canadian artificial cornea clinical trial has been enhanced by a remote, real-time 3D HD video training solution.

The study will evaluate the safety and tolerability of the R:GEN laser in patients with early-stage age-related macular degeneration.

Citing an unstable supply chain, Pfizer is discontinuing the ophthalic drops.

George Marcellino, vice president of Iridex, is being remembered by colleagues as a man of substance.

Topcon Corp. will purchase exclusive rights to distribute Iridex Corp.’s retina and glaucoma products, while also acquiring a common equity stake in the company. Iridex will acquire Topcon’s PASCAL product line.

The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.

Visits, elective procedures decreased as physicians responded to COVID-19 guidelines.

The bulk of a $25 million gift from the Henry L. Hillman Foundation will drive vision care research and development through The Eye and Ear Foundation and the University of Pittsburgh Departments of Ophthalmology and Otolaryngology.

According to a survey by the Larry A. Green Center, in collaboration with the Primary Care Collaborative (PCC) and 3rd Conversation, primary care offers assets, including experience and relationships with patients.

Gene therapies to mitigate the effects of mutations that cause blindness are undergoing rapid development. Investigators have found that novel gene vectors reduce the risks associated with these procedures.

Dr. Bath could be the first African-American woman inducted into the Hall. As the first African-American woman to receive a medical patent, for the laserphaco probe, and the first woman to lead a post-graduate training program in ophthalmology, her experience is extensive.

Findings from a new quality of life (QOL) assessment on thyroid eye disease (TED) indicate that the impact on patients extends well beyond its active phase and into the chronic phase.

The drop, formerly prescribed as Pazeo, joins Alcon’s over-the-counter ocular allergy portfolio to meet a variety of patient needs.

Applicants must submit an original essay focusing on how biologics are transforming regenerative medicine in eye care. The deadline to apply is March 12.

Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.

New World Medical relied on feedback from surgeons in the development of the device, which was registered with the FDA in October.

LumiThera has announced positive interim data in visual and ERG clinical outcomes in the ELECTROLIGHT pilot study in dry AMD patients.

To mark the 20th anniversary of its TECNIS IOLs, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery.

The session duration is 4 hours per week over the course of about 6 months, according to Jorge L. Alió, MD, PhD, FEBO, director of the course.

Rapid test allows healthcare professionals to make fast decisions at the point of care.

Investigators are studying the use of photobiomodulation in the treatment of dry age-related macular degeneration.

Following a successful Phase 2 study, a Phase 2/3 clinical trial for the compound is currently planned for mid-2021.

Investigators from the University of Pittsburgh and West Virginia University will collaborate on an international glaucoma laser study funded with a combined $15.2 million grant.

Paul S. Bernstein, MD, PhD, leads a team of University of Utah investigators that has developed a method for synthesizing large enough quantities of very-long-chain polyunsaturated fatty acids to evaluate their potential sight-preserving properties.

Bascom Palmer Eye Institute will hold its 18th annual meeting, titled Angiogenesis, Exudation, and Degeneration 2021, a virtual event set for February 12-13.

Fellows, residents from around the world show promise for future of retinal research.